RecruitingNCT07606066
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
Sponsor
AstraZeneca
Enrollment
3,000 participants
Start Date
May 6, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Participants must be ≥ 18 years of age at the time of signing the ICF.
- Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World
- Health Organization or local diagnostic standards, inadequately managed with:
- Lifestyle management alone, AND/OR
- A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.
- Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
- Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.
Exclusion Criteria3
- Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol).
- Diagnosed with Type 1 diabetes mellitus.
- Known pregnancy at the time of visit or having the intention to become pregnant.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERProcedure: assessment
The approximate volume of blood required is 2 mL
Locations(40)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07606066
Related Trials
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT0689747560 locations
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
NCT071242082 locations
Postprandial Effect of Isocaloric Challenge Meals Enriched With Indigenous Fruits and Vegetables on Glucose Metabolism in Individuals With Type 2 Diabetes in Wakiso District, Uganda
NCT072956001 location
The GRoceries Aimed at Increasing Nutrition Study
NCT071670041 location
Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D
NCT070053621 location